Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Table. 1.

Summary Characteristics of Included Studies

Author year Country Setting Study type Average age of participants (yr) Total No. Total No. in buspirone group GI condition Control Concomitant medication Baseline psychiatric status
Aggarwal, 2018 USA OP Double-blind RCT (crossover) 52.7 (9.3) 10 10
(crossover study)
Functional dysphagia/IEM Matched placebo NR
Alianova, 2019 Ukraine OP Unblinded RCT NR (range 18-45) 63 34 PDS (subtype of FD) and all H.pylori positive H.pylori eradication therapy both groups No selection: 40% had clinically significant anxiety
Ambros, 2023 Brazil OP N-of-1 trial 36 1 1 Gastric glitch (proposed new subtype of FD) Prucalopride and placebo (compared individually) NR
Caviglia, 2017 Italy OP Real world study with patients retrospectively recruited 49.9 (NR) 59 32 FD 3 separate treatment groups: buspirone vs amitriptyline vs debopride NR
Parkman, 2023 USA OP Double-blind RCT 96 47 Symptoms of gastroparesis with at least moderately severe symptoms of early satiation and/or postprandial fullness; normal upper GI endoscopy; could have normal or delayed gastric emptying Matched placebo 72% taking PPI, 26% prokinetics, 51% antiemetics, 45% antidepressants, 63% other neuromodulators (regular opiate users excluded) No selection: 39% had major depression or anxiety
Radetic, 2019 USA OP Case report 60 1 1 FD with rapid gastric emptying Nil NR
Singh, 2021 USA OP Case series 61.0 (17.1) 5 (1 per case) 5 (1 per case) EPS (n = 1), PDS (n = 2) or mixed (n = 2) - all post-fundoplication None 1 amitriptyline 10 mg, 1 mirtazapine 15 mg 1 reported anxiety
Sadiku, 2020 USA IP Case report 58 1 1 FD/gastroparesis Metoclopramide 5 mg QDS, ondansetron 4 mg QDS, famotidine 20 mg BD NR
Tack, 2012 Belgium OP Double-blind RCT (crossover) 38.5 (2.4) 17 17 (crossover study) FD Matched placebo Excluded if current anxiety or depression or treated with antipsychotics or antidepressants during last 6 weeks
Taghvaei, 2021 Iran OP Double-blind RCT NR 30 18 FD Matched placebo No selection: baseline HADS score 22.11 in buspirone group, 25.23 in placebo (no significant difference)

GI, gastrointestinal; USA, United States of America; OP, outpatient; RCT, randomized controlled trial; NR, not reported; IEM, ineffective esophageal motility; PDS, post-prandial distress syndrome; FD, functional dyspepsia; EPS, epigastric pain syndrome; H. pylori; Helicobacter pylori; OD, once daily; BD, twice daily; PPI, proton pump inhibitor; HADS, Hospital Anxiety and Depression Scale.

Data are presented as mean (SD) or n.

J Neurogastroenterol Motil 2025;31:18~27 https://doi.org/10.5056/jnm24115
© J Neurogastroenterol Motil